TY - JOUR
T1 - Tissue heterogeneity of calcium channel antagonist binding sites labeled by [3H]nitrendipine
AU - Gould, R. J.
AU - Murphy, K. M.M.
AU - Snyder, S. H.
N1 - Copyright:
Copyright 2004 Elsevier B.V., All rights reserved.
PY - 1984
Y1 - 1984
N2 - Calcium channel antagonist binding sites have been labeled in cerebral cortex, heart, ileum, and skeletal muscle with [3H]nitrendipine. While the dissociation constants of the site from cortex, heart, and ileum are similar, K(D) ≃ 0.1-0.2 nM, the value in skeletal muscle is 2 nM. This difference in affinity is also reflected in the K(i) values of dihydropyridine calcium channel antagonists, nifedipine, nimodipine, PY108068, SKF24260, and nisoldipine, and the calcium channel agonist CGP 28392, all of which show lower affinity for the skeletal muscle binding site. The diphenylalkylamine calcium channel antagonists, lidoflazine, cinnarizine, flunarizine, and prenylamine, however, show a 3- to 10-fold increase in affinity in skeletal muscle relative to the other three tissues. EDTA treatment of membranes decreases binding in cortex, heart, and ileum but increase binding in skeletal muscle. These changes are reversible upon addition of CaCl2, SrCl2, or BaCl2. The different properties of [3H]nitrendipine binding in various tissues may relate to the varying tissue sensitivity to organic calcium channel antagonists.
AB - Calcium channel antagonist binding sites have been labeled in cerebral cortex, heart, ileum, and skeletal muscle with [3H]nitrendipine. While the dissociation constants of the site from cortex, heart, and ileum are similar, K(D) ≃ 0.1-0.2 nM, the value in skeletal muscle is 2 nM. This difference in affinity is also reflected in the K(i) values of dihydropyridine calcium channel antagonists, nifedipine, nimodipine, PY108068, SKF24260, and nisoldipine, and the calcium channel agonist CGP 28392, all of which show lower affinity for the skeletal muscle binding site. The diphenylalkylamine calcium channel antagonists, lidoflazine, cinnarizine, flunarizine, and prenylamine, however, show a 3- to 10-fold increase in affinity in skeletal muscle relative to the other three tissues. EDTA treatment of membranes decreases binding in cortex, heart, and ileum but increase binding in skeletal muscle. These changes are reversible upon addition of CaCl2, SrCl2, or BaCl2. The different properties of [3H]nitrendipine binding in various tissues may relate to the varying tissue sensitivity to organic calcium channel antagonists.
UR - http://www.scopus.com/inward/record.url?scp=0021367759&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021367759&partnerID=8YFLogxK
M3 - Article
C2 - 6422256
AN - SCOPUS:0021367759
SN - 0026-895X
VL - 25
SP - 235
EP - 241
JO - Molecular Pharmacology
JF - Molecular Pharmacology
IS - 2
ER -